Agenta Biotechnologies, Inc., a private biotechnology company, announced that it has received a $1.1 million grant from the National Institutes of Health and National Institute of Dental and Craniofacial Research (NIH/NIDCR) for the further development of a biologically activated membrane to improve soft tissue healing associated with oral surgery.
The firm is exploiting its Customized Therapeutic Proteoglycan Delivery (CTPD) platform to develop proteoglycan-based therapies for tissue regeneration and healing. Agenta claims the technology allows for the precise control and manipulation of proteoglycan DNA sequences for development of products with potential applications in a wide range of regenerative uses including healing bone, cartilage, skin, and spinal discs and as coatings for vascular stents and implants.
“Eventually these improvements in spine and vertebral disc treatments may allow for repair without surgery and may also yield improvements in skin healing caused by burns, age, sun damage and diseases including diabetes,” said Dr. Arthur DeCarlo, D.D.S., Ph.D., President and Chief Executive Officer of Agenta Biotechnologies.
Agenta is currently applying its technology to the development of therapeutics for enhanced bone healing in the skull, and for growth of essential new bone in the jaw and around teeth. Using funds from a previous NIH SBIR grant directed at bone repair, the companies have already reported positive pre-clinical data and are preparing for FDA interactions as the next step toward human clinical trials.